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Introduction
Angiogenesis requires the integration of multiple cellular events 
including sprouting, invasion, lumen formation, and network 
interconnection. These events are orchestrated by the coordi-
nated effort of a complex array of intracellular signaling path-
ways, cell–cell and cell–matrix interactions. It is well recognized 
that among the multiple angiogenic factors, vascular endothe-
lial growth factor A (VEGF-A) is essential for the initiation and 
overall, regulation of vascular growth and patterning (Gerber 
et al., 1999; Jośko et al., 2000; Inoue et al., 2002; Ferrara et al., 
2003). Notably, the responses of endothelial cells to VEGF are 
regulated by the nature, frequency, and distribution of other re-
ceptors and interacting molecules (Soker et al., 1998; Bazzoni 
and Dejana, 2004; Reynolds et al., 2004; Ashikari-Hada et al., 
2005; Olsson et al., 2006). It is the combinatorial outcome of 
this input that ultimately dictates the size, type (artery vs. vein), 
and specialization of blood vessels (Wang et al., 1998; Ruhrberg 
et al., 2002; Stalmans et al., 2002; Jakobsson et al., 2006).
Two distinct receptor tyrosine kinases have been identi-
fied  for VEGF-A  on  endothelial  cells; VEGFR1  (flt-1)  and 
VEGFR2  (human  KDR/mouse  flk-1;  Mustonen  and Alitalo, 
1995; Ferrara et al., 2003; Olsson et al., 2006; Shibuya and 
Claesson-Welsh,  2006). Their  activities  and  contributions  to 
vascular morphogenesis are distinct and nonoverlapping (Fong   
et al., 1995; Shalaby et al., 1995). The affinity of VEGF-A for 
VEGFR1 is 10-fold stronger than its affinity for VEGFR2; 
nonetheless,  most  VEGF-A–mediated  downstream  signaling 
events associated with angiogenesis require VEGFR2 activation 
(Waltenberger et al., 1994; Zachary, 2005). Binding of VEGFR2   
to VEGF induces dimerization and consequent phosphoryla-
tion of a subset of intracellular tyrosine residues (Pötgens   
et al., 1994). A total of 19 tyrosine residues are located in the 
C-terminal tail of VEGFR2 and at least 7 of these have been 
V
EGF  can  be  secreted  in  multiple  isoforms  with 
variable affinity for extracellular proteins and dif-
ferent abilities to induce vascular morphogenesis, 
but the molecular mechanisms behind these effects remain 
unclear. Here, we show molecular distinctions between 
signaling  initiated  from  soluble  versus  matrix-bound 
VEGF, which mediates a sustained level of VEGFR2 inter-
nalization and clustering. Exposure of endothelial cells 
to matrix-bound VEGF elicits prolonged activation of 
VEGFR2 with differential phosphorylation of Y1214, and 
extended activation kinetics of p38. These events require 
association of VEGFR2 with 1 integrins. Matrix-bound 
VEGF also promotes reciprocal responses on 1 integrin 
by inducing its association with focal adhesions; a re-
sponse that is absent upon exposure to soluble VEGF. 
Inactivation  of  1  integrin  blocks  the  prolonged  phos-
phorylation of Y1214 and consequent activation of p38. 
Combined, these results indicate that when in the context 
of extracellular matrix, activation of VEGFR2 is distinct 
from that of soluble VEGF in terms of recruitment of recep-
tor partners, phosphorylation kinetics, and activation of 
downstream effectors.
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Results
VEGF can be retained and remains active 
within a collagen matrix
Except for VEGF121, all other VEGF isoforms have the ability to 
bind to multiple proteins and proteoglycans present in the ECM 
(Ashikari-Hada et al., 2005). To mimic in vitro the likely con-
text of VEGF presentation in vivo, we polymerized VEGF onto 
gels consisting of collagen and fibrinogen, two major compo-
nents of ECM, and tested its retention within this matrix (Fig. S1, 
A and B). This was consistent with our findings from surface 
plasmon resonance that indicate significant affinity of VEGF for 
collagen  (unpublished  data).  In  contrast,  a  mutant VEGF 
form (VEGF113) that lacks the ECM binding domain was rap-
idly released from the polymerized gel (Fig. S1, C and D). More 
than 80% of VEGF165 was maintained within the collagen gel 
after continuous washes, whereas only 20–30% of VEGF113 was 
left within the gel under the same conditions. The result indicates 
that VEGF can be retained in collagen gels, but this requires the 
ECM binding domain.
Next, we tested whether matrix-bound VEGF165 (Vb) re-
mained active by evaluating its ability to phosphorylate VEGFR2 
when compared with soluble VEGF165 (Vs) at identical concen-
trations for 5 min. This time point was selected because it results 
in maximum activation of VEGFR2 by soluble VEGF165 in vitro. 
We found that matrix-bound VEGF165 induced phosphorylation 
of VEGFR2 at equivalent levels as of soluble VEGF165 at 5 min 
(Fig. 1, A, B, and D). Activation of the receptor required direct 
contact of cells with matrix, as presence of a nylon membrane 
that prevented direct interaction no longer resulted in VEGFR2 
activation (Fig. 1 C). In contrast, the presence of such mem-
brane did not interfere with activation of VEGFR2 by Vs (Fig. 1 C). 
Activation of VEGFR2 by matrix-bound VEGF165 was repro-
duced using multiple primary endothelial cell types and with two 
commercial sources of VEGF165 (Fig. 1, B and E). Furthermore, 
lower concentrations of matrix-bound VEGF165 than soluble 
VEGF165 were sufficient to induce phosphorylation of VEGFR2 
(Fig. 1 D). Polymerized collagen in the absence of the growth 
factor did not elicit activation of VEGFR2 (Fig. 1, A, B, and D).
Matrix-bound VEGF165 increases kinetics 
of VEGFR2 activation and mediates 
clustering of the receptor
Exposure of confluent endothelial cultures to VEGF165 revealed 
prolonged activation of VEGFR2 only when the growth factor 
was bound to matrix (Fig. 1, F and G; Fig. S2, A and B). Activa-
tion of VEGFR2 did not require the release of VEGF from matrix, 
as presence of broad-spectrum matrix metalloproteinases and 
plasmin inhibitors showed identical results (Fig. 1 E; Fig. S2 C), 
further supporting the conclusion that VEGF165 bound to matrix 
can induce activation of VEGFR2.
To further explore the effect of matrix-bound VEGF165 on 
receptor function, we examined the extracellular distribution of 
receptors upon activation by Vs and Vb. We found that matrix-
bound VEGF induced receptor clustering at the cell surface 
(Fig. 2, A and B). In the absence of VEGF, visualization of the 
receptor with an extracellular binding domain antibody showed   
identified  to  be  cross-phosphorylated  by  each  monomeric   
kinase (Dougher-Vermazen et al., 1994; Takahashi et al., 2001; 
Claesson-Welsh, 2003; Blanes et al., 2007). The functional sig-
nificance of these sites to the activation of downstream signal-
ing pathways has been under investigation using both cell 
culture and animal models (Dougher and Terman, 1999; Sakurai 
et al., 2005). In fact, several phosphatases and adaptor proteins 
have been found to interact specifically with some, but not other 
phosphorylation sites assigning function to each tyrosine resi-
due (Guo et al., 1995; Kroll and Waltenberger, 1997; Huang 
et al., 1999; Wu et al., 2000; Takahashi et al., 2001; Sakurai 
et al., 2005).
At the cellular level, activation of VEGFR2 results in induc-
tion of proliferation and migration, Ca
2+ mobilization, prosta-
cyclin (PGI2) production, ERK activation, nitric oxide (NO) 
production, and phosphatidylinositol-3-kinase (PI3K)/Akt activity 
(Waltenberger et al., 1994; Kroll and Waltenberger, 1997, 1999; 
Wheeler-Jones et al., 1997; Gerber et al., 1998; Cunningham et al., 
1999). The question of how upon phosphorylation some path-
ways are preferentially selected has remained unanswered and 
halts the progress toward a more complete understanding of vas-
cular formation, homeostatic control, and regional differentia-
tion of vessels.
Another interesting aspect of VEGF biology is the large 
number of isoforms generated by this gene. Alternative splicing 
of human VEGF mRNA can give rise to at least nine different 
isoforms (Bates et al., 2002; Takahashi and Shibuya, 2005; 
Mineur et al., 2007). The most common include VEGF121 (mouse 
VEGF120), 165 (mouse VEGF164), and 189 (mouse VEGF188; 
Neufeld et al., 1996; Poltorak et al., 1997). These isoforms dif-
fer in their binding to extracellular matrix (ECM) molecules by 
virtue of the extent of the C-terminal region beyond the receptor-
binding domain (Robinson and Stringer, 2001). Notably, the 
interaction of VEGF with matrix proteins has been considered 
important for the angiogenic switch facilitating the transition 
from hyperplastic to malignant tumor formation (Bergers et al., 
2000) and for altering the susceptibility of the vasculature to 
specific chemotherapeutic drugs (Tozer et al., 2008). Recently, 
our laboratory demonstrated that VEGF isoforms can also be 
cleaved extracellularly by a subset of matrix metalloproteinases 
(MMPs) altering the status of matrix-bound isoforms to soluble 
VEGF (Lee et al., 2005). Interestingly, when mice were injected 
with tumor cells overexpressing uncleavable or soluble mutant 
VEGF forms, not only did tumor growth vary significantly, but 
also distinct vascular patterns were associated with each form. 
These in vivo results highlighted the notion that VEGF bound 
to the ECM is bioactive, confirming earlier findings in vitro (Park 
et al., 1993). Yet, the caliber of vessels, degree of vascular branch-
ing, and capillary density were distinct if the process was driven 
by uncleavable or by soluble VEGF (Lee et al., 2005). These 
findings were unexpected and required further mechanistic 
exploration. Here, we demonstrate that matrix-bound VEGF 
induces prolonged activation kinetics of VEGFR2 with altered 
patterns of tyrosine activation and subsequent downstream 
enhancement of the p38/MAPK pathway. These effects re-
quire association of VEGFR2 with 1 integrin, a previously 
unsuspected partner.597 Context-dependent VEGF signaling • Chen et al.
antibody-tagged receptor assays (Fig. 2, C–F; Fig. S3, A and B). 
Interestingly, the ratio of VEGFR2 internalization between Vs 
and Vb was similar to the respective phosphorylation levels 
(Fig. 1, F and G). To further ascertain the relationship between 
VEGFR2 internalization and phosphorylation, we investigated 
whether internalized VEGR2 remained phosphorylated using 
pan-phosphotyrosine antibodies (Fig. 2 D). Under Vb treatment, 
higher phosphorylation was noted at 15 min in comparison to 
Vs (Fig. 2 D; see Fig. 9 A). The relationship between phos-
phorylation and endocytosis was further supported by experiments 
with Dynosore, a potent dynamin inhibitor. We found that endo-
cytosis was required for VEGFR2 phosphorylation under both 
bound and soluble conditions (Fig. 2 G).
a centrally located pattern of VEGFR2. Exposure of confluent 
cells to either soluble or matrix-bound VEGF165 induced a broader 
distribution of VEGFR2 to the periphery of the cell and, in the 
case of matrix-bound VEGF165, it also resulted in formation of 
large clusters that were less predominant in cells treated with 
soluble VEGF165 (Fig. 2, A and B).
We next examined kinetics of receptor endocytosis using 
standard biotinylation assays (Fig. S3 A) and uptake of VEGFR2 
antibodies (extracellular epitope) upon exposure to Vs and Vb 
(Fig. 2, C–F; Fig. S3, B and C). Surprisingly, although Vs and Vb 
showed no major difference on receptor internalization at early 
time points (Fig. S3 C), Vb exhibited prolonged internalization ki-
netics that peaked at 15 min, as shown by both biotinylation and 
Figure 1.  Matrix-bound VEGF165 is able to phosphorylate VEGFR2. (A) Confluent PAE-KDR cultures were exposed for 5 min to matrix-bound VEGF165 
(Vb), soluble VEGF165 (Vs; 100 ng/ml and 200 ng/ml), vehicle only (2), or polymerized collagen gels. Level of VEGFR2 (210 kD) phosphorylation 
was determined by Western blot analysis using a pan-phosphotyrosine antibody (4G10). The bottom panels are blots reprobed with antibodies against 
VEGFR2, as control. (B) Confluent HUVECs, HSVECs, and HAECs were exposed to Vb, Vs, or matrix-collagen gel controls. The blots were stripped and 
reprobed with antibodies against VEGFR2 as controls. (C) Similar experiment settings as A and B using 200 ng/ml VEGF, but in the presence of a nylon 
membrane when indicated. (D) VEGFR2 phosphorylation was induced by different concentrations of Vs or Vb, as indicated. (E) VEGF165 (200ng/ml) from 
two different sources was compared under bound and soluble conditions. BB94 (MMP inhibitor, 2 µM) was incorporated within the collagen gel together 
with VEGF165. The arrows indicate different phosphorylation patterns of VEGFR2 caused by Vb treatment. The densitometry of D and E were calculated by 
p-VEGFR2 over VEGFR2 and using vehicle (2) as 1.0. (F) HUVECs exposed to either soluble (200 ng/ml) or matrix-bound VEGF165 and at the indicated 
times. Phosphorylation levels of VEGFR2 were then determined by Western blot using 4G10 antibody. Note that prolonged phosphorylation of VEGFR2 
in bound when compared with soluble VEGF165. (G) Densitometric analysis of same experiments as F (n = 4–5), shown as ratio of Vb over Vs in each time 
point (*, P < 0.05 for 10- and 20-min time point between Vb and Vs).JCB • VOLUME 188 • NUMBER 4 • 2010   598
Figure 2.  VEGFR2 clustering and internalization induced by soluble and matrix-bound VEGF165. (A) HUVECs were treated with vehicle (2), Vs (200 ng/ml), 
Vb (200 ng/ml), or collagen (col) for 15 min. Cells were fixed and stained using either rabbit Ig control (top) or antibody against extracellular domain 
of VEGFR2 in the absence of permeabilization. Computer-generated images (black and white on the right) were used for quantitation of positive staining 
of VEGFR2 (VEGFR2 distribution) and to identify particle size over 10-fold larger than controls (VEGFR2 clustering). (B) Statistical analysis for VEGFR2 
distribution and VEGFR2 clustering are shown. For VEGFR2 clustering, baseline (=1) size was assessed when cells were exposed to vehicle only 
(*, P < 0.05, between Vb to either 2, Vs, or Col). (C) Internalization of VEGFR2 was analyzed in confluent HUVECs treated with Vs (200 ng/ml),   
Vb (200 ng/ml), and vehicle controls for 15 min. To detect the internalized receptor, cells were treated first with a recombinant single-chain antibody 
against human VEGFR2 (scFvA7), subsequently exposed to Vs or Vb, followed by acid washes before fixation. Internalized VEGFR2 appears in a vesicular 
pattern. (D) Same experiments as C but analyzed by Western blots using VEGFR2 or 4G10 antibodies. Total VEGFR2 was measured from the same lysate 
used for immunoprecipitation used for internalized VEGFR2. (E) Statistics analysis of C. The results (referred to as counts per cell) were reported in the bar 
graph of three independent experiments. Six random fields were analyzed in each experiment. (F) Densitometric analysis of D. The results were from six 
independent experiments. Internalized VEGFR2 by Vs and Vb were normalized with total VEGFR2 in the lysate, and then compare normalized Vb over Vs 
in each experiment. (G) Confluent HUVECs were pretreat with Dynosore or DMSO at 37°C for 15 min. Cells were then treated with Vs, Vb, or vehicles 
(2) for 5 min. Phosphorylation assays were performed and the cell lysates were then immunoprecipitated with 4G10 and then blotted with total VEGFR2 
antibody. Total VEGFR2 was determined by using the same lysate used for immunoprecipitation. In A and C, nuclei stained with TOPRO3 appears in blue. 
*, P < 0.05; **, P < 0.005.599 Context-dependent VEGF signaling • Chen et al.
in agreement with our previous findings. Interestingly, soluble 
VEGF165 showed one additional difference: higher and prolonged 
activation kinetics of Akt, in contrast to lower Akt activation by 
Vb (Fig. 4, C and E). These findings were reproduced with mutant 
forms of VEGF that were unable to be released from the matrix 
through intramolecular cleavage (Fig. S4 B) and by using solid 
phase assay with immobilized VEGF (Fig. S4 A). Overall, these 
data indicate that presentation of VEGF (i.e., soluble vs. matrix-
bound) differentially impacts downstream effectors.
VEGF isoforms that lack matrix-retention 
domains do not support prolonged 
activation of VEGFR2
To further test the relevance of matrix anchorage on activation 
of p38, we tested VEGF121 and VEGF113 (isoforms lacking ECM 
Matrix-bound VEGF leads to prolonged 
activation of Y1214 on VEGFR2
Several potential auto-phosphorylation sites have been identified   
in VEGFR2: Y801 in the juxtamembrane domain, Y951 in the 
kinase insert, Y1054 and Y1059 in the kinase domain, and Y1175 
and Y1214 in the C-terminal tail (Dougher-Vermazen et al., 1994; 
Takahashi et al., 2001; Claesson-Welsh, 2003). Taking into ac-
count the differences in gel mobility (Fig. 1 E and Fig. 3 A) and in 
timing of activation, we considered that matrix-bound and soluble 
VEGF165 might elicit differential phosphorylation patterns. Using a 
cohort of phopho-specific antibodies, we compared levels of phos-
phorylation induced by either soluble or bound VEGF165. Initially, 
a pan-phosphotyrosine antibody (4G10) showed overall phos-
phorylation of VEGFR2 under both conditions (Fig. 3 A) at 5 and 
15 min. As shown in Fig. 1, F and G, a prolonged phosphorylation 
of VEGFR2 was frequently noted in the context of Vb treatment.
Antibodies to specific VEGFR2 phosphotyrosine residues 
were subsequently used in the same lysates analyzed in panel A 
(Fig. 3 B). At 5 min, Y951 appeared to be preferentially phosphory-
lated  by  matrix-bound VEGF165;  however,  this  residue  was 
quickly dephosphorylated (at 15 min) and could not explain the 
prolonged phosphorylation induced by matrix-anchored VEGF165. 
By 15 min, while most phosphorylation sites had returned to base-
line, Y1214 showed a substantial retention of activation exclu-
sively by matrix-bound VEGF165 and was gradually back to 
baseline levels only after 30 min (Fig. S3 E). These results indicate 
that the extended phosphorylation observed by 4G10 was likely 
mediated by retention in the phosphorylation status of Y1214.
To further ascertain whether the effect was specific, we 
used HEK 293 cells transfected with VEGFR2 mutant Y1214F 
(Fig. 3 C), as well as cells transfected with native VEGFR2 
(Fig.  3 D) and two additional VEGFR2 mutants, Y951F and 
Y1130F (Fig. S3 D). Pan-phosphotyrosine antibodies (4G10) 
were used to detect overall phosphorylation levels in VEGFR2. 
Only  the Y1214  mutation  abrogated  the  increased  levels  of 
phosphorylation on VEGFR2 upon exposure to matrix-bound 
VEGF. These findings further support the concept that matrix-
bound VEGF leads to a temporal increase in the phosphory-
lation of VEGFR2, and that this occurs through Y1214.
Matrix-bound VEGF165 leads to higher 
activation of the p38/MAPK pathway
The downstream consequences of prolonged activation of Y1214 
on VEGFR2 could be predicted based on the fact that this residue 
has been associated with activation of p38 (Lamalice et al., 2004). 
Indeed, we found that matrix-bound VEGF165 mediates higher 
and sustained activation of p38 (Fig. 4 A). Moreover, kinetics of 
p38 phosphorylation correlated with the activation kinetics of 
pY1214. This was in contrast to findings using soluble VEGF165-
treated cells where p38 peaks rapidly, but drops to basal levels 
after 5 min (Fig. 4, B and D). To better understand the overall effect 
of matrix-bound VEGF165, we conducted a protein antibody array 
analysis on nearly 40 common downstream signaling molecules, 
including all the major signaling pathways activated downstream 
of VEGFR2, such as MAPK, p38, PI3K, and Akt (unpublished 
data). Both matrix-bound and soluble VEGF165 were found to 
activate several pathways at similar kinetics, except for p38, 
Figure 3.  Prolonged phosphorylation induced by matrix-bound VEGF165 
is specific to tyrosine 1214. (A) HUVECs were incubated with Vs or Vb   
(200 ng/ml) for either 5 or 15 min, as indicated. Phosphorylation assays 
were performed and 4G10 was used as pan-phosphotyrosine antibody. 
Densitometric analysis of phospho-VEGFR2 by Vs and Vb were normalized 
with total VEGFR2 and then compare Vb over Vs as indicated. (B) Phosphory-
lation assays were performed using phosphotyrosine antibodies specific   
for the indicated residues on VEGFR2. (C) HEK 293 cell lines expressing 
Y1214F VEGFR2 mutant were incubated with soluble (Vs; 200 ng/ml) or 
bound VEGF165 (Vb) for 5 min and 15 min, vehicle (2), or collagen only 
(col) for 5 min. Equal protein levels were separated by gel electrophoresis 
and probed with 4G10. The blot was then reprobed with VEGFR2 anti-
body for normalization. Densitometric analysis of phosphorylation status 
induced by Vb to Vs is indicated. (D) Similar experiments were performed 
using HEK 293 stably transfected with native VEGFR2 (293NR).JCB • VOLUME 188 • NUMBER 4 • 2010   600
resulted in the same VEGFR2 phosphorylation kinetics, indi-
cating that the receptors were saturated at this concentration. 
  Furthermore, phosphorylation kinetics of VEGFR2 diminished 
at 15 min regardless of VEGF165 concentration if presented in a 
soluble form. Therefore, the differences in VEGFR2 phosphory-
lation kinetics induced by Vb were not the product of changes 
in VEGF stability. In addition, to compensate for the degradation 
of Vs at later time points and mimic a “slow release of VEGF” 
model, we either added the same amount of BSA as a carrier pro-
tein to stabilize VEGF or exposed cells to fresh VEGF every 5 min 
after the initial treatment (Fig. 5 E). Once again, VEGF receptors 
were saturated and the kinetics of phosphorylation were un-
altered, showing a peak at 5 min with a sharp decrease thereafter.
Matrix-bound VEGF165 induces  
association of VEGFR2 with 1 integrin 
and promotes redistribution of this integrin 
to focal adhesions
In addition to the two classical receptor tyrosine kinases, VEGFR1 
and R2, several other receptors have been shown to modulate 
VEGF signaling. For instance, VE-cadherin has been shown to 
antagonize VEGFR2 activation in confluent monolayers (Calera 
et al., 2004; Lampugnani et al., 2006), whereas neuropilins were 
found to enhance several responses downstream of VEGFR2 
(Becker et al., 2005; Kawamura et al., 2008). We suspected that 
matrix receptors, particularly integrins, and perhaps other co-
receptors might be involved in the distinct pattern of VEGFR2 
responses induced when the ligand was bound to matrix. To test 
for this possibility, we performed coimmunoprecipitation of 
VEGFR2 and subsequently asked whether other proteins were 
coprecipitated by using specific antibodies against neuropilin-1, 
VE-cadherin, VEGFR1, 1 integrin, and 3 integrin. Interestingly, 
1 integrin was found to form a stable complex with VEGFR2 
binding domain) polymerized on collagen gels for their ability 
to phosphorylate of VEGFR2, Y1214, and p38 (Fig. 5, A and B). 
Collagen polymerized with VEGF113 or VEGF121 failed to elicit 
activation of VEGFR2, in contrast to their ability to activate the 
same receptor when presented in a soluble form. We predict that 
the difference resided in the inability of these isoforms to bind 
to the ECM (Fig. S1, C and D).
Several matrix proteins were able to sustain bioactivity of 
VEGF165. In addition to type I collagen, we also examined whether 
mixtures of VEGF165 with type IV, V, and VIII collagen could 
elicit similar prolonged activation on Y1214 at 15 min (Fig. 5 C). 
Although activation levels of pY1214 were not as strong as those 
seen on type I collagen, all these matrices led to higher phosphory-
lation retention of Y1214 than those detected by soluble VEGF, 
supporting the concept that multiple matrix proteins can mediate 
immobilization and possibly result in a similar outcome.
Prolonged activation of VEGFR2 by Vb is 
not due to local concentration of VEGF165
To control for potential confounding differences in VEGF half-
life as result of exposure to different solutes, we analyzed the 
stability of VEGF165 under both soluble and matrix-bound con-
ditions. VEGF165 in PBS was less stable than when mixed with 
collagen (Fig. S1, E and F). Nonetheless, it should be stressed 
that the timing used on the phosphorylation assays was short 
(5 and 15 min) and minimally affected by the half-life of VEGF 
in solution (100 min). Therefore, differences of VEGF165 stability 
would provide a negligible variation, if any, to the experimental 
outcomes. Yet, to further support the conclusions, we performed 
an additional assessment of VEGFR2 phosphorylation using sol-
uble VEGF165 at higher concentrations and examined whether 
these conditions would change the kinetics of receptor activation 
(Fig. 5 D; Fig. S1 G). VEGF165 concentrations above 150 ng/ml 
Figure 4.  p38 and Akt pathways are differentially induced by soluble and matrix-bound VEGF165. (A) Confluent HUVEC cultures were incubated in the 
presence or absence of soluble (Vs) or matrix-bound VEGF165 (Vb; 200 ng/ml) for 5 min. Cell lysates were obtained, resolved by SDS-PAGE, and probed 
with antibody against phospho-p38 (43 kD). The blot was then stripped and reprobed with total p38 antibodies for normalization. (B) HUVECs were 
exposed to Vs or Vb (200 ng/ml) at the indicated times. The blot was then stripped and reprobed with total p38 antibody for normalization. (C) Same 
settings as B, but membrane was immunoblotted with phospho-Akt (S473) and total Akt (60 kD). Densitometry was determined by phospho-p38 over total 
p38 (n = 6) (D) or phospho-Akt over total Akt (n = 6) (E).601 Context-dependent VEGF signaling • Chen et al.
with soluble VEGF165 alone (Fig. 8 A). Furthermore, prolonged 
phosphorylation of VEGFR2-Y1214 induced by matrix-bound 
VEGF165 at 15 min was no longer detected if the cells were 
pretreated with 1 integrin inhibitory antibodies (Fig. 8 B). The 
association of VEGFR2 and 1 integrin triggered by matrix-
bound VEGF was also disrupted when 1 integrins were blocked 
(Fig. 8 C). It is also important to notice that pretreatment of 
1 integrin inhibitory antibodies did not alter the phosphorylation 
of Y1214 at early time points (Fig. S5 A), consistent with the 
fact that association with 1 integrin only occurs later (Fig. 6 A).
We further determined the contribution of 1 integrin to 
the specific phosphorylation of VEGFR2 using genetic loss-
of-function experiments. Mouse liver endothelial cells (MLECs) 
were  isolated  from  1
floxed/floxed  (1
fl/fl)  mice,  and  exposed  to 
  either adeno-Cre virus or control adenovirus. Evaluation of 1 
integrin levels, as well as presence of Cre-recombinase, showed 
a significant reduction of the integrin in the samples that also ex-
pressed Cre (Fig. 8, D and E, bottom two panels). Down-regulation 
of this integrin did not trigger significant morphological changes 
when plated on vitronectin (Fig. S5 B). Experimental and con-
trol cultures were then treated with soluble or bound VEGF 
and probed with antibodies against Y1214, Y1175, and GAPDH 
(Fig. 8, D and E, top panels). In agreement with previous find-
ings, only matrix-bound VEGF165 led to prolonged phosphory-
lation of Y1214 in wild-type MLECs after 15 min of treatment, 
whereas both soluble and bound VEGF165 resulted in equivalent 
exposed to Vb, but not to Vs (Fig. 6 A; Fig. S4 D). From all the 
other cell surface proteins examined, we noted that association 
of VEGFR2 with neuropilin-1 was enhanced by soluble VEGF165, 
as previously shown (Soker et al., 1998; Kawamura et al., 2008). 
Surprisingly, less neuropilin-1 was found associated to VEGFR2 
when cells were exposed to Vb (Fig. S4 C). This was also sup-
ported by reverse immunoprecipitation (not depicted).
Low  levels  of  1  integrin  were  found  associated  with 
VEGFR2 in the absence of VEGF165 (Fig. 6 A). Interestingly, 
the association was consistently lost upon exposure to soluble 
VEGF165, but enhanced when the ligand was bound to matrix 
(Fig. 6 A). This result was further validated using proximity 
ligation assays (Fig. 6, B and C). We also found that matrix-
bound VEGF165 induces redistribution of 1 integrins to focal 
adhesions (Fig. 7, A and B). This tropism for focal adhesions 
did not occur when endothelial cells were exposed to either 
growth factor–free collagen or to soluble VEGF165.
1 integrin/VEGFR2 association is required 
for the increased activation of Y1214  
and p38
The contribution of 1 integrins to the prolonged responses 
of p38 and Y1214 under matrix-bound VEGF165 treatment 
was challenged by 1 integrin inhibitory antibodies. Pretreat-
ment of cultures with inhibitory antibodies blocked prolonged 
phosphorylation of p38 that now was equivalent to treatment 
Figure 5.  Prolonged activation of VEGFR2 requires matrix-binding motifs in VEGF. (A) Various VEGF isoforms (165, 121, 113; 200 ng/ml) were polymer-
ized with collagen as indicated. The gel was prepared and washed as described in Materials and methods and placed on confluent monolayers for 5 min. 
Phosphorylation assays were performed and total VEGFR2 levels were determined by reprobing the same membrane. (B) Same as A, but treated for 15 min and 
probed with antibodies against pY1214 (top) or pP38 (bottom). Numbers on the bottom of the Western blot indicate densitometric quantification. (C) Differ-
ent collagen types were used to anchor VEGF (Vb, 200 ng/ml) as indicated. Exposure to collagen matrices for 15 min resulted in prolonged phosphoryla-
tion of Y1214. (D) Dose curve of VEGFR2 activation by VEGF. Detection of phosphorylation was performed using 4G10 antibodies. Numbers below the 
Western blotndicate densitometric quantification at 15 min using 100 ng/ml VEGF165 treatment as 1.0. (E) 500 ng/ml of VEGF165 was used on cells for 5, 
15, and 30 min in the presence or absence of a carrier to stabilize the protein. On the right, 500 ng/ml of VEGF was used at time 0, and an additional 
fresh aliquot at 500 ng/ml was added at indicated time points for another 5 min. Phosphorylation assay was performed using 4G10 antibody.JCB • VOLUME 188 • NUMBER 4 • 2010   602
Together, these findings support the conclusion that asso-
ciation of 1 integrin with VEGFR2 is induced by matrix-bound 
VEGF and it is critical for the prolonged phosphorylation re-
sponses found specifically in Y1214 and downstream activation 
of the p38 MAPK pathway.
1 integrin is required for the prolonged 
internalization of VEGFR2 and clustering 
induced by matrix-bound VEGF165
We next investigated whether association with 1 integrin was 
required for the induction of VEGFR2 clustering and increased 
internalization. Pretreatment of cultures with inhibitory 1 inte-
grin antibodies blocked clustering and prolonged internal-
ized VEGFR2 at 15 min by Vb, which was now equivalent to 
treatment with soluble VEGF165 (Fig. 9, A and B).
Based on these findings, we propose a model in which 
matrix-bound VEGF progressively facilitates proximity and sub-
sequent binding to 1 integrins (Fig. 9 C). This interaction medi-
ates receptor clustering and redistribution of 1 integrins to focal 
adhesions. Furthermore, the interaction of VEGFR2 to 1 inte-
grin selectively favors retention of the phosphorylation status of 
one residue (Y1214), resulting in changes in downstream of pP38.
Discussion
VEGF is a master regulator of endothelial differentiation during 
development (Carmeliet et al., 1996; Ferrara et al., 1996) and it 
is also required for homeostatic functions of blood vessels in the 
adult, including permeability and endothelial survival (Lee et al., 
2007; Nagy et al., 2008). Nonetheless, it has remained unclear 
how VEGF elicits such a vast array of cellular responses, which 
are mostly downstream of VEGFR2. Our results showed that 
the presentation of VEGF in either soluble or matrix-bound form 
alters the kinetics of receptor activation, impacts association with 
other cell surface receptors, and modulates signal transduction 
pathways downstream VEGFR2 activation. Matrix-bound VEGF 
induces receptor clustering, association with 1 integrin, and the 
initiation of a pro-migratory phenotype on endothelial cells that 
is reminiscent of tip cells (Gerhardt et al., 2003). These effects 
are dependent on 1 integrin, as pharmacological or genetic 
inactivation of this molecule suppressed the differential signal-
ing events initiated by matrix-bound VEGF. Overall, these find-
ings demonstrate that VEGFR2 activation can be mediated 
by VEGF when in association with matrix proteins and further 
indicate that this activation is likely be relevant to the estab-
lishment of the tip cell phenotype during the formation of a 
vascular sprout.
Activation of VEGF receptors by VEGF in the context 
of matrix has been previously noted, but not fully character-
ized (Park et al., 1993). Studies using modified VEGF to 
make it covalently bound to the matrix have shown that under 
those conditions, VEGF can lead to increase proliferation of 
endothelial cells (Zisch et al., 2001; Koch et al., 2006). We 
have confirmed and extended these experiments, providing 
molecular explanation for the potential relevance of the dis-
tinct VEGF isoforms and a function for the avidity of VEGF 
for matrix proteins.
activation of Y1175. Once 1 integrin was genetically inactivated, 
Vb was no longer able to sustain phosphorylation on Y1214, 
in agreement with the results using 1 integrin inhibitory anti-
bodies. However, we did notice that there was a substantial 
decrease between 1
ECKO cells and control cells on pY1175 
levels even though equivalent protein was loaded (as per GAPDH). 
Further investigation showed that levels of VEGFR2 were de-
creased in the absence of 1 integrins (1
ECKO cells; Fig. S5 C), 
a difference that appears to be post-transcriptional (Fig. S5 D). 
Interestingly, albeit reduced, VEGFR2 was phosphorylated but 
unable to support prolonged activation of p38 in the absence of 
1 integrin (Fig. 8 F).
Figure 6.  VEGFR2 associates with 1 integrin when exposed to matrix-
bound but not soluble VEGF165. (A) Confluent HUVEC monolayers were 
incubated with soluble (200 ng/ml) or bound VEGF165 (200 ng/ml) and 
collagen for 5, 15, and 30 min. Cultures were then lysed and equal cell 
lysates were used for immunoprecipitation with VEGFR2 antibodies. The 
precipitated protein was then resolved on 4–12% SDS-PAGE and probed 
with a 1 integrin antibody (130 kD). The blot was then reprobed with 
anti-VEGFR2. (B) Representative images of proximity ligation assays with 
quantification (C) after treatment with the indicated growth factors. Red 
dots denote regions of signal amplification consistent with VEGFR2/1 
integrin interactions. Nuclear stain is TOPRO3 (blue) (n = 4; *, P < 0.05 
between Vb to either 2, Vs, or Col).603 Context-dependent VEGF signaling • Chen et al.
Matsumoto and Claesson-Welsh, 2001), an association between 
1 integrins and VEGFR2 has been tested but not found. Simi-
larly to those studies, we were not able to coimmunoprecipitate 
both receptors in the presence of soluble VEGF (Figs. 6 and 8). 
Nonetheless, we found that matrix-bound VEGF significantly in-
creased the ratio of 1 integrin associated with activated VEGFR2 
in a time-dependent manner, with maximum phosphorylation at 
15 min and still clearly detectable by 30 min. This association 
was biologically significant and necessary for the selective and 
continued phosphorylation of VEGFR2-Y1214 and for the in-
crease in p38. Furthermore, matrix-bound but not soluble VEGF 
induced redistribution of 1 integrin to focal adhesions.
Modulation of VEGFR2 responses by other cell surface 
receptors has been described for VE-cadherin and for neuropilin. 
In the case of VE-cadherin, it has been noted that clustering 
of cadherins suppresses VEGFR2 activation by reducing recep-
tor internalization and activation within endocytosed vesicles 
(Lampugnani et al., 2006). Thus, VE-cadherin appears to be a 
negative regulator of VEGFR2 function. Consistent with this role, 
more recently it has been found that VE-cadherin phosphory-
lates MLC2, leading to suppression of sprouting (Abraham et al., 
2009). In contrast, activation of neuropilin appears to mediate 
VEGFR2 activation, migration, and sprouting (Wang et al., 2003; 
Becker et al., 2005; Pan et al., 2007; Kawamura et al., 2008; 
The biological meaning of the association of VEGF with 
the ECM has been studied using transgenic mice by placing the 
coding region of the three major VEGF isoforms (188, 164, and 
120) downstream of the VEGF promoter (Ruhrberg et al., 2002). 
Mice expressing VEGF188, a form that exhibits significant affin-
ity for matrix proteins, showed enhanced vascular branching and 
increased capillary density when compared with either wild-type 
controls or mice with exclusive expression of VEGF164. In con-
trast, mice expressing VEGF120 (little to no affinity for matrix) 
displayed lack of filopodia extension, poor branching, formation 
of vascular tufts, and enlarged vessel diameter (Ruhrberg et al., 
2002). Overall, the affinity of VEGF for matrix conveys informa-
tion with significant consequences to vascular morphogenesis. 
Although it has been clear that VEGFR2 is the main receptor for 
these signaling events, our understanding of VEGFR2 activation 
in the context of matrix is limited.
It has been speculated that association of VEGFR2 with 
coreceptors or other cell surface proteins was likely responsible 
for the broad spectrum of responses mediated by VEGF. We con-
sidered that integrins might play a role in the case of matrix-
bound VEGF, as the presence of matrix proteins would naturally 
mediate integrin engagement. Furthermore, 1 integrin has long 
been shown to be involved in angiogenesis. Although binding of 
VEGFR2 to 3 integrin has been described (Borges et al., 2000; 
Figure 7.  1 integrin redistributes to focal adhesion upon stimulation by matrix-bound VEGF165. HUVECs treated at the conditions indicated for 15 min 
were fixed and stained for 1 integrin (red), paxillin (green), and TOPRO3 (blue). Arrows (A and B) indicate colocalization of 1 integrin and paxillin, 
arrowheads in B show focal adhesions without 1 integrin–positive staining. Asterisks in A indicate cells with higher expression of 1 integrin, to indicate 
that regardless of the diffused expression of 1 integrin only, Vb, but not Vs, resulted in redistribution of the integrin to focal adhesions. (A) Lower magni-
fication; (B) higher magnification of independent experiments.JCB • VOLUME 188 • NUMBER 4 • 2010   604
organization of clusters has been recognized for other receptor 
tyrosine kinases (Abu-Ali et al., 2008; Wang et al., 2009), this 
has not been noted for the VEGF receptor family. Our results in-
dicate that VEGFR2 clustering might provide an important mean 
to deliver a more robust and prolonged signal needed to sustain a 
migratory response and within the context of focal adhesions. 
Given the large array of ECM combinations in distinct tissues, an 
obvious consideration is whether other integrins might be able to 
substitute for 1 heterodimers. Although we still do not have the 
answer to this question, one might speculate that this is likely to 
be the case and that the matrix molecule, rather than the integrin 
subtype, might dictate the molecular nature of the cluster.
In a broader perspective, the information unraveled by 
these studies provides rationale to further investigate the rele-
vance of surface patterning of VEGF in bioactive materials 
(Anderson et al., 2009). It is likely that the combination of physi-
cal and chemical cues presented at a nanoscale level and within 
Valdembri et al., 2009). Thus, putting these results together it 
appears that neuropilins and 1 integrins facilitate and enhance 
VEGFR2 activation, whereas clustering and engagement of 
VE-cadherin  suppresses  VEGFR2  phosphorylation  but  pro-
motes capillary morphogenesis and vascular maturation.
Another interesting effect found with matrix-bound VEGF 
was induction of receptor clustering. Both bound and soluble 
VEGF induced a rapid movement of VEGFR2 receptors from 
the center to the cell periphery. Notably, although clustering was 
already seen when cells were exposed to collagen, the size of the 
clusters and their association to focal adhesion only occurred 
when nanomolar levels of the growth factor were incorporated 
in the matrix. The relevance of receptor clustering to signal-
ing events has been well characterized in neurobiology and 
immunology, where functional synapses correspond to well-
orchestrated arrangements of clustered molecules in respond 
to a stimuli (Cochran et al., 2001; Griffith, 2004). Although 
Figure 8.  Blocking 1 integrin dampens activation of pY1214 and P38 of matrix-bound VEGF165. (A) Confluent HUVEC monolayers were starved for 6 h   
and pretreated with 1-inhibiting antibodies for 15 min, then treated with the indicated reagents for an additional 15 min. Cell lysates were collected, 
resolved on 4–12% SDS-PAGE, probed with phopho-p38 antibody, and reprobed with total p38 antibody. (B) Same as A, treated with indicated reagents 
for 15 min and probed with antibody against pY1214. Membranes were then stripped off and reprobed with total VEGFR2 antibody. (C) HUVECs were 
treated as in A. Cell lysates were collected and immunoprecipiated with VEGFR2 antibodies. Immunoprecipitated proteins were probed with anti-1 inte-
grin or anti-VEGFR2. The top panel shows cells without preincubation with 1-inhibiting antibodies. The bottom panel shows cells preincubated with 
1-inhibiting antibodies. (D) Mouse liver ECs from 1
fl/fl mice were isolated and treated with adeno-Cre virus to induce deletion of the gene. After 3 d, 
cultures were treated with indicated growth factors for 15 min and cell lysates were probed with pY1214, GAPDH (36 kD), and 1 antibodies. Blots were 
then stripped and reprobed with anti-Cre (35 kD). (E) Similar experimental setting as D but probed with pY1175. (F) Confluent 1
fl/fl or 1
ko MLEC mono-
layers in 96-well plates were starved overnight and exposed to the indicated treatments for 5, 15, or 30 min. p38 activation was determined by cell-based 
ELISA and the fold change at each time point was calculated by phospho-p38 over total p38 compared with no treatment. The difference between pP38 
activation in WT and KO cells is statistically significant at 15 and 30 min. *, P < 0.05 (n = 4).605 Context-dependent VEGF signaling • Chen et al.
Technologies) were cultured in complete MCDB 131 medium (VEC Tech-
nologies). Porcine aortic endothelial cells transfected with VEGFR2 (PK 
cells; a gift from Gera Neufeld, Technicon, Israel) were grown in Ham’s 
F-12 medium with 10% fetal bovine serum (Omega Scientific). HEK 293 cells 
transfected with native VEGFR2 or mutants (a gift from Bruce I. Terman) were 
grown in DME high glucose with FBS (10% vol/vol) and 10 µg/ml puro-
mycin (Sigma-Aldrich). Human VEGF165 was either provided by the NIH 
Repository, Genentech (San Francisco, CA), or purchased from R&D Sys-
tems. mVEGF113 was generated as described previously (Lee et al., 2005). 
VEGF121 was provided by Gera Neufeld or purchased from R&D Systems. 
Rabbit anti–human VEGFR 2, phospho-VEGFR 2 (Tyr996 and Tyr1175), 
p38 MAPK, phospho-p38 MAPK (Thr180/Tyr182), Akt, and phospho-Akt 
(S473) were from Cell Signaling Technology. Antibodies to phosphotyro-
sine (4G10), mouse anti–human VEGFR2, rabbit anti-phospho VEGFR2 
(Tyr951, Tyr1054, Tyr1059), and anti-1 integrins were from Millipore. 
Rabbit anti-phospho VEGFR2 (Tyr 1214) was from Invitrogen. Rabbit anti-
phospho  VEGFR2  (Tyr801)  was  from  ECM  Biosciences.  Rabbit  anti-1 
  integrin (C-terminal) was purchased from Abcam. 1 integrin inhibitory 
antibody was purchased from Covance. Neuropilin-1 antibody was pur-
chased from Santa Cruz Biotechnology, Inc. VEGF antibodies were pro-
vided by Donald Senger (Beth Israel Deaconess Medical Center, Boston, 
MA). For the detection of internalized VEGFR2, anti–human VEGFR2 
(single-chain recombinant; clone scFvA7 with E tag; RDI and Fitzgerald) in 
combination with rabbit anti–E-tag (Abcam) were used for immunofluores-
cence. Antibodies against the extracellular domain of VEGFR2 were provided 
an organized array might serve to direct cell migration and fur-
ther design patterns of vascular morphogenesis.
Overall, based on these findings we would like to introduce 
the concept that the presentation of VEGF (either soluble or 
bound) conveys distinct functional responses through the same 
receptor. Although this work focused on VEGFR2 and 1 inte-
grin, it is likely that other receptors, such as neuropilin, plexin, 
and Notch are also likely to play an integrative role in the con-
text of bound versus soluble VEGF. Additional efforts should try 
to investigate how the combinatorial interpretation of matrix-
anchored or soluble VEGF in concert with other receptors alters 
morphogenesis and functional efficacy of blood vessels in a 
tissue-specific manner.
Materials and methods
Cells and reagents
Human aortic endothelial cells (HAECs) (a gift from Judith Berliner, UCLA, 
Los Angeles, CA), human umbilical vein endothelial cells (HUVECs; VEC 
Technologies), and human saphenous vein endothelial cells (HSVECs; VEC 
Figure 9.  1 integrin is required for clustering and continued internalization of VEGFR2. (A) Internalization of VEGFR2 was analyzed in confluent HUVECs 
pretreated with 1 inhibitory antibodies or Ig control for 15 min, and then treated with Vs (200 ng/ml), Vb (200 ng/ml), and vehicle controls for another 
15 min. To detect the internalized receptor, cells were treated with a recombinant single-chain antibody against human VEGFR2 (scFvA7), subsequently 
exposed to the indicated treatment followed by acid washes before lysis. Internalized VEGFR2 was analyzed by Western blot using VEGFR2 or 4G10 
antibodies. Total VEGFR2 was determined in the same lysates. The numbers indicate densitometric analysis comparing Vs and Vb. (B) HUVECs pretreated 
with 1 inhibitory antibodies or Ig control for 15 min were exposed to vehicle (2), Vs (200 ng/ml), Vb (200 ng/ml), or collagen (col) for 15 min. Cells   
were fixed and stained using recombinant single-chain antibody against human VEGFR2 (scFvA7) with E-tag in the absence of permeabilization. FITC- 
conjugated anti–E-tag was used for detection of positive staining. Nuclei stained with TOPRO3 appears in blue. (C) Schematic model depicting the inter-
action of soluble and matrix-bound VEGF with VEGFR2. Soluble VEGF (left) results in rapid binding, internalization, and activation of VEGFR2. Matrix-bound 
VEGF (right) interacts easily with receptors as the cells migrate into the matrix. The affinity for the matrix is two orders of magnitude lower than its receptor. 
Over time, the progressive recruitment of integrins facilitates clustering of VEGFR2 and results in binding between integrins and VEGFR2. This interaction 
maintains the phosphorylation status of Y1214.JCB • VOLUME 188 • NUMBER 4 • 2010   606
for indicated times and finally washed (three washes with ice-cold 50 mM 
glycine in Ca
2+/Mg
2+ HBSS, pH 2.5, followed by two washes with Ca
2+/
Mg
2+ HBSS, pH 7.5) to remove any residual antibody/growth factor from 
the cell surface.
To detect internalized VEGFR2 by immunofluorescence studies, cells 
were fixed in 1% PFA in 2.5 mM triethanolamine, pH 7.5, containing 
0.1% Triton X-100 and 0.1% NP-40 for 25 min at room temperature. Be-
fore staining, 0.5% Triton X-100 in PBS was added for 10 min at room 
temperature (Lallemand et al., 2003). The distribution of the primary anti-
body was revealed with rabbit anti–E-tag (Abcam) followed by FITC-
conjugated donkey anti–rabbit. To detect internalized VEGFR2 by Western 
blots, cell lysates were collected as previously described. Lysates were   
immunoprecipitated  with  rabbit  anti–E-tag  (Abcam)  and  separated  by 
SDS-PAGE. Internalized VEGFR2 was then revealed by anti-VEGFR2.
Proximity ligation assay
HUVECs grown on Labtek chamberslides (Thermo Fisher Scientific) were 
starved for 6 h and incubated in the presence or absence of soluble VEGF 
(200 ng/ml), bound VEGF, or collagen alone for 20 min. Cells were 
washed with chilled PBS and fixed with 4% paraformaldehyde for 15 min, 
blocked, permeabilized, and incubated overnight with mouse anti–VEGF-R2 
(Millipore) and rabbit anti-1 integrin (Abcam) as indicated. Proximity 
ligation was performed according to the manufacturer’s protocol using the 
Duolink Detection Kit with PLA PLUS and MINUS Probes for mouse and 
rabbit (Olink Bioscience; Söderberg et al., 2006; Jarvius et al., 2007). 
TOPRO3  nucleus  stain  (Invitrogen)  was  added  to  the  mounting  media 
(Olink Bioscience) at 1:1,000 and examined with a confocal microscope 
(LSM 510 Meta; Carl Zeiss, Inc.) under a 60x oil objective. Texas red (or 
Cy3) signal amplification was scanned in only the red channel and counted 
by Blob Finder V3.2 (Uppsala University, Sweden). Four fields at 600x 
were randomly chosen for analysis and averaged per condition, examin-
ing four independent preparations individually.
Immunocytochemistry and confocal microscopy
Endothelial cells were grown on Labtek chamberslides (Thermo Fisher Scien-
tific) and treated as indicated. Cultures were fixed with 4% paraformalde-
hyde for 15 min at room temperature and permeabilized with 0.1% Triton 
X-100 in 1x PBS. F-actin was detected using Texas red–conjugated phalloidin 
(Invitrogen) diluted 1:40 in 1% BSA/PBS. TOPRO3 nucleus stain (Invitrogen) 
was added in the mounting media (90% glycerol + 10x PBS) at 1:1,000; 
  antibody against the extracellular domain of VEGFR2 was diluted 1:100 in 
1% BSA/PBS. Antibodies against paxillin (Abcam) and 1 integrin (BD) were 
also used 1:100 in 1% BSA/PBS. Slides were then examined under a con-
focal microscope (LSM 510 Meta; Carl Zeiss, Inc.) under a 60x oil objective.
Quantitation of VEGFR2 clustering
Images were collected randomly (10 images from each treatment; 3 individ-
ual experiments were evaluated), and the calculations were determined with 
the “analyze particles” function of ImageJ (NIH) by using all 10 random 
  images from each treatment, with particle threshold size over 10 for positive 
VEGFR2 distribution and over 100 for positive VEGFR2 clustering.
Statistical methods
Data  and  graph  were  evaluated  using  a  Student’s  two-tailed  t  test  or 
ANOVA with GraphPad Prism 4 software. In all analyses, P < 0.05 was 
taken to be statistically significant.
Isolation of endothelial cells from 1
fl/fl mice
Transgenic mice with loxP sites flanking the 1 integrin locus (1
fl/fl) have 
been previously described (Raghavan et al., 2000). Mice were perfused 
with 1x PBS and collagenase (500 µg/ml in DME; Sigma-Aldrich). Livers 
were harvested and incubated in collagenase (500 µg/ml) for another 
30 min. Supernatants were mixed with equal volume of DME containing 
20% FBS. Cells were collected after centrifugation at 2,000 rpm for 5 min, 
resuspended, and filtered through a 40-µm pore size top filter (BD). Filtered 
cells were plated onto fibronectin/vitronectin-coated tissue culture dishes 
and washed after 2–3 h to remove cell debris and remaining blood cells.
To inactivate the 1 integrin gene, the isolated endothelial cells 
were incubated with 1:1,000 adeno-Cre virus stock for 1 h with serum-free 
media or with adenoviral vector alone. After initial 1 h, complete media 
(20% FBS) was added and cells were incubated overnight at 37°C. Cells 
were cultured for an additional 3 d before experimentation.
Examination of p38 activation on 1
KO cells
To  assess  the  p38  activation  on  1
KO  mouse  endothelial  cells,  cells 
(30,000 cells/well) were plated onto 96-well plates and cultured for 2 d 
by Rolf A. Brekken (UT-Southwestern, Dallas, TX). Collagen matrix (Purecol) 
was from Advanced Biomatrix. BB94 was a gift from Gerry Weinmaster 
(UCLA, Los Angeles, CA).
Matrix-bound (Vb) and soluble (Vs) VEGF165 preparation
To  generate  matrix-bound  VEGF  (Vb),  indicated  concentrations  of  the 
growth factor (different isoforms as indicated) were mixed with neutralized 
Purecol collagen gel (3.0 mg/ml; Advanced Biomatrix) and allowed to 
polymerize at 37°C for 1 h on plastic wrap. The solidified gel was then 
immersed in 4 ml of 1x PBS for 10 min. The process was repeated five 
additional times to remove majority of unbound VEGF. The gel was then 
placed on top of confluent endothelial monolayers. Control gels were done 
without any VEGF165 added. Soluble VEGF165 was diluted into 1x PBS into 
same concentration as matrix-bound VEGF165 and used as is.
To challenge direct contact of cells with the matrix, nylon membranes 
were used in some experiments. In such experiments, the gel was then 
transferred on top of a 40-µm cell strainer (Millipore) as a “holder” with the 
bottom of the strainer covered by an 8-µm nylon membrane. The device 
loaded with collagen gel containing growth factor was then transferred onto 
a confluent monolayer of HUVECs with serum-free media for 5 min. The gel 
was covered by the media but did not touch cells directly. The cells were 
then collected and phosphorylation of VEGFR2 was determined as described 
below. Under this condition, soluble VEGF165 could diffuse, but bound 
VEGF165 was unable to diffuse from the gel. When specified we also used 
VEGF113 and VEGF121; the incorporation of these into matrix was done in 
a similar manner as described for VEGF165.
VEGF release and retention assays
To determine the release of VEGF from polymerized matrix gels, 2 ml of 
collagen-bound VEGF was allowed to polymerize in a 50-ml falcon tube. 
50 ml of 1x PBS was then added to the tube and incubated under gentle 
agitation. At indicated times, a 200-µl aliquot was removed and the level 
of VEGF released was determined by ELISA (R&D Systems).
To indirectly assess the amount of VEGF retained in the collagen gel, 
2 ml of collagen-bound VEGF was polymerized in one 35-mm well, washed 
with 4 ml of 1x PBS, and the concentration of VEGF in each wash was 
measured by ELISA. Retained VEGF was estimated considering the initial 
input and the levels released by each wash.
To directly assess matrix-retained VEGF and its half-life, collagen-
bound and soluble VEGF were made as described in the previous sub-
heading. Then both types of VEGF (Vb and Vs) were incubated at 37°C at 
indicated times. To measure the levels of VEGF bound to matrix, gels were 
placed on ice for 30 min to depolymerize and then either mixed with 
  Laemmli buffer and boiled for 10 min for Western blot or diluted 50 times 
into sample buffer for ELISA analysis.
Immunoblotting and immunoprecipitation
Endothelial cells were lysed in RIPA buffer (50 mM Tris, pH 7.4, 150 mM 
NaCl, 1% NP-40, 0.25% sodium deoxycolate, 1 mM EDTA, 1 mM sodium 
vanadate, 10 mM -glycerophosphate, and protease inhibitors [1 mM phenyl-
methanesulfonylfluoride (PMSF), 20 µg/ml leupeptin, and 20 µg/ml apro-
tinin]). Cell lysates were further incubated under agitation at 4°C for 30 min, 
and then centrifuged at 20,000 g for 30 min at 4°C. Equivalent levels 
(500 µg) of protein, determined using the DC protein assay reagent (Bio-Rad 
Laboratories), were precleared by TrueBlot anti–rabbit Ig IP beads (eBiosci-
ence) and immunoprecipitated overnight at 4°C with the antibody of interest. 
Immune complexes were retrieved using the TrueBlot anti–rabbit Ig IP beads. 
Immunoprecipitates were washed three times with the same lysis buffer and 
then separated by SDS-PAGE. Proteins were then transferred to nylon mem-
branes (GE Healthcare), probed with indicated antibodies, and detected by 
an enhanced chemiluminescence technique (Thermo Fisher Scientific). After 
detection, the results were quantified by densitometry using ImageJ (Na-
tional Institutes of Health, Bethesda, MD). Protein phosphorylation was deter-
mined by immunoblotting as described previously (Luque et al., 2003).
VEGFR2 internalization assay
Cells were precooled for 30 min on ice and subsequently incubated with 
10 µg/ml of monoclonal anti–VEGFR2 antibodies (RDI and Fitzgerald) 
for an additional 30 min under gentle agitation. The VEGFR2 monoclonal 
antibodies recognize the extracellular domain of human VEGFR2, lack 
biological activity, and do not interfere with VEGF-mediated activation of 
the receptor. These antibodies were used previously in internalization 
experiments (Lampugnani et al., 2006). After exposure to the antibodies 
and before stimulation with VEGF, cells were washed with ice-cold 1% 
BSA in MCDB 131 to remove unbound antibody, and fresh medium was 
added. Cells were stimulated with either Vs, Vb, Col, or vehicle at 37°C 607 Context-dependent VEGF signaling • Chen et al.
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